Five-Year Disease Prevalence Only One Driver of R&D Investment
The five-year figure doesn't always determine which cancer types are most commonly being studied in late-phase trials.
Five-year disease prevalence is certainly a factor-but apparently not the only one-determining which cancer types are most commonly being studied in late-phase clinical trials. IMS Health's analysis of the distribution of Phase III trials reveals that, as would be expected, cancers with higher five-year disease prevalence are the subject of more late-phase trials. But there are exceptions (see Figure 1).
The first is lung cancer. It is the clear leader in terms of the volume of Phase III trials, yet has about the same five-year prevalence as cervical and stomach cancers, both of which are involved in dramatically fewer trials. This may be tied to the fact that the molecular targets in non-small cell lung cancer have been long-since identified and extensively studied. The second exception is ovarian cancer, which has one of the lowest five-year prevalence rates, but is being heavily studied in Phase III trials due to the fact that several genetic mutations can affect the outcome for ovarian cancer patients.
Thus, a low five-year disease prevalence does not always inhibit research investment, provided that the genetic target can be identified in patients. - IMS Health
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
